Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVACNASDAQ:FSTXNYSE:NUVBNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$3.20-0.9%$3.11$2.21▼$5.28$716.42M2.48808,831 shs507,601 shsFSTXF-star Therapeutics$7.12$6.19$2.07▼$7.12$156.50M0.85709,213 shsN/ANUVBNuvation Bio$1.88-6.9%$2.00$1.54▼$3.97$636.72M1.472.05 million shs3.42 million shsTRVITrevi Therapeutics$6.10-1.6%$5.38$2.30▼$7.39$589.76M0.411.93 million shs765,254 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac-1.22%+18.75%+7.31%-20.64%+21.89%FSTXF-star Therapeutics0.00%0.00%0.00%0.00%0.00%NUVBNuvation Bio0.00%+22.36%-5.15%-22.12%-29.69%TRVITrevi Therapeutics+4.20%+16.98%-8.15%+62.30%+120.64%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac3.3511 of 5 stars3.21.00.04.81.80.01.3FSTXF-star TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANUVBNuvation Bio2.4651 of 5 stars3.60.00.00.03.53.30.6TRVITrevi Therapeutics3.3953 of 5 stars4.72.00.00.02.64.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 2.33Hold$10.00212.50% UpsideFSTXF-star Therapeutics 0.00N/AN/AN/ANUVBNuvation Bio 3.25Buy$8.75365.43% UpsideTRVITrevi Therapeutics 3.30Buy$17.56187.91% UpsideCurrent Analyst Ratings BreakdownLatest FSTX, CVAC, TRVI, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/19/2025TRVITrevi TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $20.003/19/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.50 ➝ $12.503/19/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/19/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $24.003/12/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/11/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/11/2025TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $20.003/10/2025NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/10/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $12.50(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$543.28M1.32N/AN/A$2.50 per share1.28FSTXF-star Therapeutics$21.17M7.39N/AN/A$4.70 per share1.51NUVBNuvation Bio$7.87M80.87N/AN/A$2.76 per share0.68TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58M$0.825.82N/AN/A20.72%21.98%15.72%4/23/2025 (Estimated)FSTXF-star Therapeutics-$31.28M-$1.82N/AN/AN/AN/A-57.08%-42.40%N/ANUVBNuvation Bio-$75.80M-$2.26N/AN/AN/AN/A-21.89%-17.86%5/13/2025 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.47N/AN/AN/AN/A-63.31%-57.06%5/6/2025 (Estimated)Latest FSTX, CVAC, TRVI, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NUVBNuvation Bio-$0.16N/AN/AN/A$0.42 millionN/A5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13N/AN/AN/AN/AN/A4/23/2025Q4 2024CVACCureVac$0.27-$0.1656-$0.4356N/A$20.58 million$15.01 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AFSTXF-star TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.206.19FSTXF-star Therapeutics0.153.383.38NUVBNuvation BioN/A9.579.57TRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%FSTXF-star Therapeutics31.50%NUVBNuvation Bio61.67%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipCVACCureVac2.15%FSTXF-star Therapeutics3.20%NUVBNuvation Bio5.07%TRVITrevi Therapeutics24.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880223.88 million219.07 millionOptionableFSTXF-star Therapeutics8421.98 million21.28 millionNot OptionableNUVBNuvation Bio60338.68 million319.50 millionOptionableTRVITrevi Therapeutics2096.68 million58.13 millionOptionableFSTX, CVAC, TRVI, and NUVB HeadlinesRecent News About These CompaniesTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $17.56 Consensus Price Target from BrokeragesApril 15 at 1:29 AM | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsApril 14 at 3:23 AM | marketbeat.comTrevi Therapeutics management to meet with Cantor FitzgeraldApril 11, 2025 | markets.businessinsider.comTraders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)April 11, 2025 | marketbeat.comLandscape Capital Management L.L.C. Has $215,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)April 11, 2025 | marketbeat.comTrevi Therapeutics Target of Unusually Large Options Trading (NASDAQ:TRVI)April 11, 2025 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)April 10, 2025 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 9.3% - Should You Sell?April 10, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming April Investor ConferencesApril 3, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Here's What HappenedApril 2, 2025 | marketbeat.comShort Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 23.5%April 2, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $34,630.54 in StockMarch 26, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Up 5.7% - Should You Buy?March 26, 2025 | marketbeat.comRosalind Advisors Inc. Has $4.38 Million Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)March 23, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for TRVI EarningsMarch 22, 2025 | marketbeat.comQ2 EPS Estimates for Trevi Therapeutics Reduced by B. RileyMarch 22, 2025 | marketbeat.comLeerink Partnrs Issues Positive Outlook for TRVI EarningsMarch 22, 2025 | marketbeat.comB. Riley Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Earnings BeatMarch 20, 2025 | marketbeat.comEarnings call transcript: Trevi Therapeutics Q4 2024 reports mixed resultsMarch 20, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSTX, CVAC, TRVI, and NUVB Company DescriptionsCureVac NASDAQ:CVAC$3.20 -0.03 (-0.93%) As of 04:00 PM EasternCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.F-star Therapeutics NASDAQ:FSTXF-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Nuvation Bio NYSE:NUVB$1.88 -0.14 (-6.93%) As of 03:58 PM EasternNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Trevi Therapeutics NASDAQ:TRVI$6.10 -0.10 (-1.61%) As of 04:00 PM EasternTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
